Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03344536 | A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT02479230 | Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients | completed | Phase 1 | 18 | Joseph Baar, MD, PhDOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT02627274 | A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 9 | Nov 22, 2022 | clinicaltrials |
| NCT00807859 | Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer | completed | Phase 1 | 65 | AmgenINDUSTRY | 3 | Nov 8, 2022 | clinicaltrials |
| NCT03368196 | DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein | completed | Phase 1 | 12 | Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo CompanyINDUSTRY | 1 | Nov 3, 2022 | clinicaltrials |
| NCT03473639 | A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy(Breast49) | completed | Phase 1 | 13 | University of VirginiaOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT01795586 | A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients | completed | Phase 1 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT02489448 | Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 68 | Yale UniversityOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT00623831 | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen | completed | Phase 1 | 17 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT02448771 | A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer | completed | Phase 1 / Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT03364348 | 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer | completed | Phase 1 | 18 | George W. Sledge Jr.OTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT00976131 | Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer | completed | Phase 1 | 7 | Columbia UniversityOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT01975831 | A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | completed | Phase 1 | 104 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02285179 | Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen(Poseidon) | completed | Phase 1 / Phase 2 | 189 | The Netherlands Cancer InstituteOTHER | 4 | Oct 12, 2022 | clinicaltrials |
| NCT02310464 | Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects | completed | Phase 1 | 25 | OBI Pharma, IncINDUSTRY | 1 | Oct 3, 2022 | clinicaltrials |
| NCT01676753 | Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer | completed | Phase 1 | 32 | Jo ChienOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT01730118 | Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2022 | clinicaltrials |
| NCT01791985 | AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)(RADICAL) | completed | Phase 1 / Phase 2 | 52 | Imperial College LondonOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT02650817 | Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer | completed | Phase 1 | 16 | Stemline Therapeutics, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT02278965 | Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer | completed | Phase 1 | 19 | Katherine D. CrewOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT03945604 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC | completed | Phase 1 | 32 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 12, 2022 | clinicaltrials |
| NCT04852419 | A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS | completed | Phase 1 | 12 | Zentera Therapeutics HK LimitedINDUSTRY | 1 | Aug 11, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT02657343 | An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. | completed | Phase 1 / Phase 2 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT04176757 | A Study of ZN-c5 in Participants With Breast Cancer | completed | Phase 1 | 35 | Zeno Alpha Inc.INDUSTRY | 3 | Aug 1, 2022 | clinicaltrials |
| NCT02684032 | A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer | completed | Phase 1 | 141 | Celcuity IncINDUSTRY | 1 | Jul 27, 2022 | clinicaltrials |
| NCT02719691 | Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer | completed | Phase 1 | 47 | University of Colorado, DenverOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02071862 | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | completed | Phase 1 | 210 | Calithera Biosciences, IncINDUSTRY | 1 | Jul 20, 2022 | clinicaltrials |
| NCT04261218 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer | completed | Phase 1 | 19 | Translational Research in OncologyOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT02120469 | Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer | completed | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03075462 | A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | completed | Phase 1 | 98 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT02623751 | Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer | completed | Phase 1 | 15 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04105582 | Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells | completed | Phase 1 | 5 | Universidad Nacional de ColombiaOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT01498458 | Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer(PazoX) | completed | Phase 1 | 9 | GBG Forschungs GmbHOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT03518242 | Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer | completed | Phase 1 | 100 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT02379247 | BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer | completed | Phase 1 / Phase 2 | 43 | Priyanka SharmaOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT02513472 | Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)(ENHANCE-1) | completed | Phase 1 / Phase 2 | 258 | Eisai Inc.INDUSTRY | 1 | May 5, 2022 | clinicaltrials |
| NCT01033032 | Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 78 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT02897778 | Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors | completed | Phase 1 | 30 | Syndax PharmaceuticalsINDUSTRY | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05344729 | Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects | completed | Phase 1 | 16 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT01134250 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | completed | Phase 1 / Phase 2 | 48 | Philogen S.p.A.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT03366428 | Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer | completed | Phase 1 | 51 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01655225 | A Study of LY3023414 in Participants With Advanced Cancer | completed | Phase 1 | 156 | Eli Lilly and CompanyINDUSTRY | 3 | Apr 8, 2022 | clinicaltrials |
| NCT02076620 | L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours | completed | Phase 1 | 29 | Philogen S.p.A.INDUSTRY | 2 | Apr 4, 2022 | clinicaltrials |
| NCT00317603 | Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients | completed | Phase 1 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT00880464 | Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer | completed | Phase 1 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT02364492 | A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse(MAGTRIVACSEIN) | completed | Phase 1 | 20 | Institut PasteurINDUSTRY | 1 | Apr 1, 2022 | clinicaltrials |
| NCT02646748 | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | completed | Phase 1 | 159 | Incyte CorporationINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02111850 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2022 | clinicaltrials |
| NCT01724606 | Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) | completed | Phase 1 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Nov 25, 2022source: clinicaltrials